Dan Weissmann
Depending on whom you ask, Alfred Engelberg might be a hero or a villain within the story of American prescription drugs. The patent lawyer helped write laws that led to a dramatic increase within the number of generic drugs available on the market. He additionally contributed to a patent system that offers pharmaceutical firms monopolies on their most profitable medication, blocking generic competitors and holding costs excessive alongside the best way.
An Arm and a Leg host Dan Weissmann traces Engelberg’s story again greater than 50 years, from a scrappy childhood on the Atlantic City boardwalk to watching President Ronald Reagan signal his invoice into legislation on the White House Rose Garden. Today, Engelberg advocates for coverage modifications he believes will allow extra generic medication to achieve the market quicker.
Dan Weissmann
Host and producer of “An Arm and a Leg.” Previously, Dan was a workers reporter for Marketplace and Chicago’s WBEZ. His work additionally seems on “All Things Considered,” Marketplace, the BBC, 99% Invisible, and “Reveal,” from the Center for Investigative Reporting.
Credits
Emily Pisacreta
Producer
Claire Davenport
Producer
Adam Raymonda
Audio wizard
Ellen Weiss
Editor
Click to open the Transcript
Transcript: Why medication price a lot, 101: Medicine monopolies
Note: “An Arm and a Leg” makes use of speech-recognition software program to generate transcripts, which can include errors. Please use the transcript as a software however test the corresponding audio earlier than quoting the podcast.
Dan: Hey there–
We are kicking off a brand new sequence right here — We’re calling it An Arm and a Leg 101.
We’ve spent years of reporting on two large questions: Why does well being care price so freaking a lot? And what can we possibly do about it?
We’ve been chasing solutions one story, one query at a time.
Now, we’re pulling collectively a few of what we’ve discovered. Digging slightly deeper, going slightly broader.
Starting with why so many medication price a lot.
One of the primary questions I ever requested — one in all our first tales — was: How can insulin be so costly? Wasn’t it found within the early twentieth century? Shouldn’t it’s a generic drug by now?
You know, low-cost?
And a part of the reply I bought was: Insulin has been reworked for the reason that early twentieth century. Lots.
A medical researcher named Jing Luo informed me: Today’s insulins are a good distance from what we had 100 years in the past.
Jing Luo: They’ve been actually modified at a molecular stage. It’s cool stuff. It’s tremendous cool stuff. And you recognize, there are a number of Nobel prizes in physiology and drugs which have made this occur.
Dan: And all that super-cool stuff, these wonderful discoveries, bought patented.
Meaning: The patent-holders– the pharma firms — bought a monopoly on these wonderful discoveries.
The pharma firms claimed patents — and monopolies– on a bunch of different issues too. Not all of them wonderful.
But every new patent can imply one other delay for a generic model coming to market.
Jing Luo: Companies can stack dozens of patents on high of one another to attempt to thwart generic competitors as a result of they will say, look, we’ve bought three patents on the lively ingredient. We’ve bought patents on the medical makes use of of the lively ingredient. We’ve bought patents on the non-active excipient related to this ingredient. We’ve bought a number of patents on the gadgets, and so that you who’re attempting to enter this house will sue you for patent infringement on all of them.
Dan: A patent ensures you at the least a 20-year monopoly. Drugs can usually get an additional 5.
And these further patents — secondary patents –can maintain you protected LONGER. If you don’t file them similtaneously the unique:
To speak about a drug that’s within the information proper now. The authentic patent on the lively ingredient in Wegovy and Ozempic truly expired this yr.. The further 5 years extends it to the early 2030s.
But dozens of additional patents — secondary patents, filed later — imply that right here within the U.S., we would not see cheaper generic variations till 2042. Or later.
And as Jing Luo informed me: This technique isn’t a secret. It’s an trade cornerstone.
Jing Luo: When you pay attention to those like CEOs of pharma firms being interviewed at CNBC, you recognize, they’d be like, nicely, what about generic competitors for this product? And they’ll simply maintain saying, no, no, no. We’ve bought this actually sturdy patent portfolio. We can face up to any problem. We’re gonna tie this up in courts perpetually and don’t fear about it.We’re gonna proceed this gravy boat for an extended, very long time. That’s the best way they reinsure traders.
Dan: A sturdy patent portfolio. ?Or what researchers and advocates name a patent thicket.
They say high quality issues lower than amount.
The numbers are wild.
According to one study, the ten best-selling medication for 2021 — medication for most cancers, HIV, arthritis — had been protected by a mixed whole of seven hundred and forty-two patents. With tons of extra “pending.”
When these add-on patents get challenged in courtroom, they really get tossed out extra typically than main patents..
But lawsuits price cash. A sturdy patent portfolio — a patent thicket — means generic firms would must be able to file a LOT of them.
So, we needed to know: How did all this occur? How did these video games get began?
It seems, there’s one man who can inform you the story from the start, for higher and for worse. Who helped form it. Made thousands and thousands of {dollars} from it. Saw its flaws. And has spent many of the final 30 years attempting to repair them. Hie’s a lawyer named Al Engelberg, and he’s 86 years previous.
Alfred Engelberg: I inform individuals on a regular basis, I reside in a world, a pharma world the place half the individuals suppose I’m useless and the opposite half want I used to be.
Dan: Al Engelberg’s story is the story of generic medication in America. And it’s a wild trip.
This is An Arm and a Leg — a present about why well being care prices so freaking a lot, and what we will possibly do about it. I’m Dan Weissmann. I’m a reporter, and I like a problem. So the job we’ve chosen right here is to take one of the crucial enraging, terrifying, miserable components of American life, and convey you one thing entertaining, empowering, and helpful.
?Al Engelberg’s mother and father fled Nazi Germany within the late Thirties.
He was born right here, lower than a yr after they arrived. They had nothing.
And right here’s the place they made their new life.
Retro information reel: We are flying over a widely known japanese metropolis. That is outstanding as a result of manufacturing is nearly non-existent. A metropolis whose precept enterprise is the leisure of thousands and thousands. Atlantic metropolis, typically referred to as the holiday capital of the nation
Dan: Al likes to say he discovered most of what he is aware of about training legislation on the Atlantic City boardwalk, by the point he was 16.
Alfred Engelberg: We grew up very, very quick there. I began working after I was about 9 or 10 and, and there have been a lot of alternatives on the boardwalk.
Dan: His first “job” was crawling round below the boardwalk, searching for free change.
Alfred Engelberg: But I went on to work at hotdog stands and at an unlawful bingo recreation for the native mob.
Dan: And in each job, Atlantic City drove residence its main lesson: Cheating — hustling — is one thing you’ve gotta anticipate.
At this unlawful bingo parlor, Al’s job was strolling between tables, doling out bingo playing cards for a dime apiece. The bosses employed school children to stroll behind children like Al, to maintain him trustworthy.
Alfred Engelberg: I imply, these guys are operating an unlawful recreation, however they nonetheless must rely, they usually nonetheless inherently don’t belief anyone.
Dan: Which was appropriate. Al says the school children had their very own hustle: They’d have him put aside a greenback or two earlier than delivering his dimes — break up that greenback with him fifty-fifty — and inform the bosses Al’s rely was high quality.
Alfred Engelberg: And all people figuring out that the counts had been wildly inaccurate anyway ‘trigger the little previous women had been, had been stealing playing cards. Everybody within the room had their very own factor going, you recognize, from the purchasers on.
Dan: After Al made it out of Atlantic City, his distinctive on-the-job training continued. He studied chemical engineering at Drexel, then took a job as a patent examiner whereas going to legislation faculty at evening.
And at that job, he discovered: The patent system was ripe for hustling.
Partly as a result of most of his colleagues weren’t essentially giving the job their all.
Like him, most patent examiners had been working their manner by legislation faculty. And they had been sneaking time to check on the job.
Alfred Engelberg: We used to have the ability to reduce our notes down in order that they slot in these file drawers with the patents. And we’d be studying your notes and in case your boss got here by, you’d simply drop a patent on high of the notes.
Dan: You might say it was Atlantic City once more. Everybody within the job is sneaking one thing for themselves — on this case, time.
And Al Engelberg might see that, even when his colleagues gave it their all, they had been too inexperienced to do their job nicely.
A patent examiner’s job — deciding whether or not a proposed invention deserves a monopoly (which at the moment was 17 years) — means deciding whether or not the concept for that invention can be apparent to “a person of ordinary skill in that field.”
Alfred Engelberg: And many of the examiners had by no means labored in that area and had completely no thought. And that is the large leagues. You’re granting any individual a monopoly for 17 years, and it appeared ridiculous on its face.
Dan: Al reduce his personal path on the patent workplace. He’d labored his manner by engineering faculty, in manufacturing crops, he noticed what individuals of extraordinary ability in that area resolve issues day-after-day. So he specialised in analyzing patents he truly knew one thing about.
That bought him promoted, then it bought him recruited by a company lawyer.. After the corporate paid his manner by the remainder of legislation faculty, he jumped to the Justice Department.
He was bold– he needed expertise junior legal professionals don’t often get — like attempting instances of his personal.
After just a few years doing simply that, he took a job with a small legislation agency in New York City in 1968.
Alfred Engelberg: I got here to New York to personal observe on the age of 30 and I used to be able to go. I imply, I used to be able to, to tear the world aside and I did.
Dan: Patents had been nonetheless a specialty. Then, in 1973, he will get a name that results in his first generic drug case.
Generic medication weren’t a scorching market on the time.
Alfred Engelberg: ?The generic drug trade in Nineteen Seventies was primarily, a half a dozen, privately owned household companies, principally within the metropolitan New York space. And many of the medication that they had been promoting had been medication that had been accredited earlier than 1962.
Dan: Yeah. 1962 is when the FDA made it tougher to get a brand new drug accredited — you needed to undergo lengthy medical trials to indicate that your drug was secure and efficient.
Even in case your drug was a generic model of an present drug. Those little firms didn’t have the capital to run these trials, in order that they had been caught promoting these previous medication.
Not a lot of a enterprise. Maybe 20 % of prescriptions had been for generic medication.
So when Al Engelberg bought a name for his first generic drug case, that was the context. And the case itself didn’t sound promising. For one factor:
Alfred Engelberg: The name wasn’t even from the consumer. It was from a financial institution. The consumer was bankrupt.
Dan: The consumer was bankrupt. This bankrupt consumer, Premo Pharmaceuticals, was getting sued for patent infringement. The financial institution was keen to place up ten thousand {dollars} for a protection. Nowhere close to sufficient to truly strive a case. Oh, and…
Alfred Engelberg: From what they informed me, the knowledge they gave me, we didn’t have an excellent protection.
Dan: But Al Engelberg noticed a gap. He might see that his opponents have weaknesses too.
Alfred Engelberg: The patent house owners had been in a really unusual place. If they received, they bought nothing as a result of we had been already bankrupt. Two, they had been gonna should spend the authorized charges to win.
Dan: Win towards a younger lawyer named Al Engelberg who already had a rep as a tricky opponent. So they might lose.
Alfred Engelberg: And in the event that they misplaced, they might lose thousands and thousands and thousands and thousands of {dollars} in enterprise as a result of there wouldn’t be a patent. And they’d have competitors from generic medication.
Dan: And in the meantime, Al Engelberg can be sizing up the decide. He is aware of the man doesn’t love patents.
So Al reveals as much as the primary convention and he bluffs.
Alfred Engelberg: I stated to the decide, oh, your Honor, you recognize, it’s one other a kind of patents. They’re all invalid. And I stated, we don’t want very a lot discovery. We’re, we’ll be able to go to trial in just a few months. Just set a trial date.
Dan: The different aspect walks out beside themselves.
And inside a few weeks they name Al to say: Hey, how about this? You guys simply acknowledge our patent is OK, and we’ll provide the cash we’d’ve spent litigating. Call it 400,000 bucks?
Alfred Engelberg: I referred to as the consumer and stated, how’s $400,000? He stated, are you kidding?
Dan: They didn’t simply get out of bother — they bought out of chapter, with $400,000 of their pockets. Because Al Engelberg knew the best way to measurement up a state of affairs.
Alfred Engelberg: You don’t be taught that in legislation faculty. That’s not what they educate.
Dan: Word will get round about that case, and fairly quickly all people within the generic drug world is asking him.
It’s a small world, however by the top of the Nineteen Seventies, there could also be room for it to start out getting larger.
People are beginning to discover: Drugs are costly. Maybe there must be extra low-cost generics.
Some generic drug firms kind an affiliation and begin lobbying: Make it simpler to get generic medication to market with out having to undergo all these trials.
The brand-name drugmakers push again: They say it takes so lengthy to run the trials and get their medication accredited, they don’t get sufficient time to earn cash earlier than these patents expire.
In 1983, Democratic Representative Henry Waxman steps in to dealer a compromise, with Republican Senator Orrin Hatch.
And Mr. Engelberg goes to Washington. To run technique for the generic drugmakers.
Alfred Engelberg: In a whole lot of methods , that’s the place my Atlantic City coaching actually helped me on the finish of the day
Dan: There had been lots of people, with a whole lot of pursuits. A variety of angles. ?He begins commuting from New York to Washington DC a pair occasions per week — for months and months, greater than a yr.
And Al Engelberg says: This time, it wasn’t nearly profitable a case.
Alfred Engelberg: I used to be behind a cab the best way I bear in mind, with the senior companion of the legislation agency. And he says to me, why are you breaking your ass going to Washington two or thrice? Why don’t you ship an affiliate? You know, it’s identical to, it’s simply one other case. And I stated. I stated, are you kidding? I stated, you recognize, what number of legal professionals ever get to do what I’m doing proper now? To be on the desk influencing what could also be a serious legislation that’s gonna have main penalties is, is like one thing I by no means thought my entire life I’d be doing.
Dan: A child from Atlantic City was precisely the suitable individual to attempt to stability all of the angles, negotiate a compromise. It took greater than a yr. It virtually didn’t occur. But then it did. Congress handed the invoice, and President Ronald Reagan bought in entrance of cameras to signal it.
Ronald Reagan: Let me flip my consideration to the true cause we’re right here this afternoon, signing into legislation the Drug Price Competition and Patent Term Restoration Act of 1984.
Dan: higher generally known as Hatch-Waxman.
Hatch Waxman had three fundamental elements:
One: Brand drugmakers bought just a few further years on their patents.
Two: Generic drugmakers bought a pathway to get FDA approval.
And three –The new legislation laid out guidelines for a generic drugmaker once they needed to CHALLENGE an present patent.
Negotiating that third half was the half the place Al Engelberg’s training on the Atlantic City boardwalk, and the U.S. patent workplace, and the generic drug trade got here collectively: The outcome would make him thousands and thousands and thousands and thousands of {dollars} — and blow an enormous gap into the grand cut price he had labored so arduous to result in.
That’s coming proper up.
This episode of An arm and a Leg is produced in partnership with KFF Health News. That’s a nonprofit newsroom protecting well being points in America. The of us at KFF Health News are wonderful journalists — their work wins every kind of awards, yearly. We are honored to work with them.
So. The brand-name drug makers and the generic drug makers struck a deal. That deal was good for them. Both sides bought one thing massive out of it. The public was presupposed to get one thing out of it too.
And, to be honest, we did: Remember, again then, possibly one out of 5 prescriptions was for a generic drug. Now it’s 9 out of ten.
But we pay greater than ever for medication. Mostly for branded, patent-protected medication. And the most important, most-important, most worthwhile medication get locked behind patent thickets.
How did that occur?
Well, to know that, it helps to know what Al Engelberg bought out of the entire cut price.
Al had been there on the bargaining desk, on behalf of the generics.
One day, throughout these negotiations, he was within the workplace with Henry Waxman’s lead counsel, a man named Bill Corr, when Corr bought a name from somebody on the opposite aspect.
Corr begins pointing on the telephone, pointing to Al — indicating: This man is speaking about you.
When Corr will get off the telephone he says: That man’s undecided about this deal the place dangerous patents might be challenged. He’s suspicious about the place you may take this. Like, are you simply gonna arrange a bounty-hunting operation, to get patents declared invalid?
And Corr stated, Al, would you try this?
Alfred Engelberg: And I stated, you recognize, Bill, till this second, I’ve by no means given it any thought, but it surely’s a hell of a good suggestion. Maybe I’ll have a look at it.
Dan: And he did. Starting virtually as quickly as Hatch-Waxman turned legislation.
Alfred Engelberg: And we sat within the rose backyard, September twenty third, 1984, watched Reagan signal the invoice. And in December of that yr, I sat down at my kitchen desk with a yellow pad and I laid out a technique.
Dan: If you had been gonna arrange a bounty-hunting operation, how would you do it?
Al Engelberg knew a whole lot of patents had been rubbish. Knew it from his time within the patent workplace, knew it from training legislation. And he knew how a lot cash a profitable patent problem might be value.
The manner Hatch-Waxman labored: If a generic drug firm challenged a patent and received, they might get six months earlier than any OTHER generic drugmakers might get a crack on the market.
So their solely competitors can be the model. If a tablet price two cents to make, and the model was promoting for a greenback a tablet — that’s 98 cents of revenue for each tablet.
You’re the one competitor? You might cost 75 cents a tablet and get 73 cents of revenue. On successful drug, you possibly can make thousands and thousands and thousands and thousands — simply in these six months.
Al’s thought was this: Partner up with a generic drugmaker. Go discover instances– medication with weak patents. Win ’em.
And break up these thousands and thousands in potential earnings fifty-fifty.
Al pitched a generic drugmaker — they had been able to go — and introduced the deal to his legislation agency. .
Alfred Engelberg: As it turned out, my companions weren’t fascinated about having me do that. They tried to speak me out of it.
Dan: But they couldn’t. So he left. Went out on his personal. All on his personal.
Alfred Engelberg: I by no means employed a single soul, not even a secretary. And I couldn’t kind. I nonetheless can’t kind.
Dan: But he hunted and pecked his manner by temporary after temporary. He purchased an early moveable laptop — it weighed thirty kilos — and lugged it round behind his automotive. For ten years.
Alfred Engelberg: It was silly. I virtually killed myself. But, it labored out okay.
Dan: Yeah. Turns out Al was actually good at discovering the issues with drug patents.
In one in all his first instances, Al Engelberg personally made greater than 70 million {dollars}. Others settled: Just a few million right here, just a few million there– it provides up.
And then…
Alfred Engelberg: It bought to be the mid nineties, and I used to be engaged on a case referred to as Buspar.
Dan: The Buspar case ended up an enormous winner for Al Engelberg and his generic drug companions.
But it had penalties that went manner past a single case. And led to massive losses for the general public.. Here’s the way it went.
Alfred Engelberg: Buspar was an anti-anxiety drug. And by all accounts not an excellent one.
Dan: But Bristol Meyers Squibb invested in massive promoting and advertising and marketing campaigns.
Speaker 5: I really feel anxious. I can’t focus.
Speaker 6: I’m so irritable. If you. You endure from extreme fear. It can really feel like a mountain of tension.
Speaker 5: I’ll by no means get all of it performed. I’m overwhelmed.
Speaker 6: But a prescription medicine referred to as buspar may also help.
Dan: And all that advertising and marketing did its job. By the mid-Nineteen Nineties, Buspar was making greater than 200 million {dollars} a yr for Bristol.
Alfred Engelberg: The solely downside for them was that the drug was not new.
Dan: The lively ingredient was well-known in medical literature as a tranquilizer. Nobody had bothered to promote it.
So Bristol Myers Squibb filed a patent on it, claiming it had found a brand new use for this well-known tranquilizer: Treating nervousness.
Al Engelberg says when he learn the patent utility, he might barely imagine it: What do tranquilizers do if not… deal with nervousness?
It’s like saying: There’s these items referred to as sugar. We’re gonna take out a patent on utilizing it as a sweetener.
This appeared like a case for a man from Atlantic City.
Alfred Engelberg: I did one thing that legal professionals don’t. That’s simply the best way I used to be constructed.
I filed a movement with the courtroom and principally stated, we don’t want any proof.
You simply should learn the patent. If you imagine it’s true, the patent’s invalid. Just, you recognize, all you want is a dictionary principally.
Dan: Al says Bristol was desirous to settle.
Alfred Engelberg: We get right into a settlement dialogue and we maintain saying, no, no, no, no.
Dan: Al’s companions had performed the maths: They figured they stood to make 100 million {dollars} or extra as soon as they received. So when the opposite aspect supplied 25 million, no was the straightforward reply.
Alfred Engelberg: We stated, why are we gonna take this? You know, it’s loopy. There’s a reward right here we all know what it’s. We’re gonna get it will definitely.
Dan: Al sits down with a lawyer from the opposite aspect, a man he is aware of, explains how he sees the maths.
And quickly the opposite aspect comes by with a a lot larger supply: 72 million {dollars} – virtually thrice as a lot.
Alfred Engelberg: And I’m sitting there like, what are you loopy? But then give it some thought from their viewpoint.
Dan: Paying 72 million {dollars} is nothing, in comparison with what Bristol stands to realize if this lawsuit goes away.
With their monopoly, Bristol Meyer Squibb is making greater than 200 million {dollars} a yr on Buspar. And until any individual else traces as much as do what Al Engelberg had performed, anticipate to maintain that monopoly for years.
Charging no matter they need. Two {dollars} a tablet, three {dollars} a tablet. Which Al Engelberg says is precisely what occurred.
In truth, they saved that monopoly for like 5 years.
Alfred Engelberg: As it turned out, no one got here behind us. And so, that they had that monopoly till 2000. So they bought 5 years of two billion, in gross earnings.
Dan: They made out.
Alfred Engelberg: For the price of $75 million. And you recognize, the general public bought screwed ’trigger they’re persevering with to pay, you recognize, $2 a tablet or $3 a tablet for a drug that finally finally ends up being out there for 20 or 30 cents. Um, in order that’s, that’s the way it works.
Dan: That’s the way it works. The branded firm and the generic firm each make out nice. Cheaper generic variations of a drug get delayed.
That wonderful payday for Al Engelberg and his companions on the generic drug firm was a mannequin a template for the form of deal that each generic drug firm would need in on.
It bought a nickname: Pay for delay.
Alfred Engelberg: That unfold by the trade like wildfire, these numbers, you recognize, you don’t make these numbers half a cent at a time on, on capsules,
Dan: Lawsuits had been far more worthwhile.
But Al Engelberg wasn’t submitting them.
A yr or so after the Buspar case settled, sparking the Pay for Delay gold rush, he retired. He had loads of cash and nothing to show.
And in retirement, he began evaluating what he’d achieved, for higher and for worse.
For higher, generic medication had greater than doubled their share of the market since Hatch-Waxman took impact.
For worse, he might see two locations the place — regardless of all of his Atlantic City coaching — he had missed a few angles in negotiating Hatch-Waxman.
One was: this entire pay-for-delay scheme. Turned out, in balancing incentives for manufacturers and generic makers, he’d left open this perverse incentive that left the general public out.
And the second was a loophole that Hatch-Waxman had left open.:
It created a course of the place gamers like Al and his generic companions might problem patents on medication like Buspar, that they thought didn’t deserve protected monopolies. It eliminated some friction for these assaults.
The drug firms developed a manner so as to add extra friction: stacking further patents — secondary patents — on each drug.
Developing patent thickets.
Even if a secondary patent is trivial — and plenty of them do get tossed out — difficult it means a courtroom battle. And that prices cash.
Alfred Engelberg: It induced the large drug firms to simply get increasingly patents. Because why not? You know, there was nothing standing in the best way.
Dan: I imply, no one is aware of higher than Al Engelberg: Patent examiners don’t precisely stand in the best way.
And these patent thickets and pay for delay, they feed on one another.
Alfred Engelberg: The economics of the enterprise, induced these sorts of settlements to achieve epic proportions. So the generic firms would, problem these secondary patents and, the drug firms would pay them off.
Dan: In 1999 he revealed an article in a scholarly journal arguing that Hatch-Waxman wanted a reboot. Even the six-month head begin for a profitable problem might most likely go.
And ever since — for greater than twenty-five years — he’s poured thousands and thousands of {dollars} into efforts to tighten the principles. Funding analysis. A public-information marketing campaign from Consumer Reports. Even a middle for IP legislation at his alma mater, NYU.
It hasn’t at all times gone his manner.
Pay for delay has gotten a lot larger since Al Engelberg wrote his first article calling for reform: He wrote in 1999 that about two dozen patent challenges had been filed.
Now he estimates that quantity at twelve thousand.
Alfred Engelberg: I can’t inform you what number of tens of billions of {dollars} in authorized charges that’s. It’s one of many quickest rising and and steadiest industries for giant legislation.
Dan: A Hatch-Waxman litigation discussion board on LinkedIn has greater than fourteen thousand members.
And Hatch-Waxman doesn’t cowl a lot of in the present day’s the top-selling medication– the most important moneymakers. They belong to a category referred to as “biologics.”
That consists of famously-expensive rheumatoid arthritis medication like Humira and Enbrel — and insulin.
Biologics weren’t a class forty years in the past when Hatch-Waxman bought negotiated. Congress handed a brand new legislation to take care of them in 2010 — ?the Biologics Price Competition and Innovation Act.
Al Engelberg will not be a fan of that legislation.
Alfred Engelberg: Whatever errors had been made in Hatch Waxman, they had been multiplied by 10 and intentionally within the biologics legislation
Dan: He says the all however encourages patent thickets. And doesn’t present a pathway to problem them.
He says it reminds him of a few of his early days training legislation.
Alfred Engelberg: Back within the seventies, we used to have small startup purchasers within the laptop area, and they might get letters from IBM. It says, we’re prepared to tell you that you could be be infringing a number of of the next patents. And there was a ten web page listing of patents hooked up. And the startup would come to us and say, you recognize, what ought to we do? And we’d say, discover one other line of labor, you recognize, what are you gonna do?
Dan: But he has not given up. In 2025, he revealed a e book: Breaking the Medicine Monopolies.
It tells the story of his profession — and lays out his prescriptions for fixing the issue.
He doesn’t JUST concentrate on plugging the holes in Hatch-Waxman and the biologics legislation.
Alfred Engelberg: You know, we don’t really need a generic drug trade. We want generic drug pricing.
Dan: He’s bought proposals for an elevated authorities position in negotiating and regulating costs — and greater than that.
He argues {that a} 1980 legislation permits the federal government to commisssion generic variations of medicine that had been developed utilizing public analysis {dollars}.
He additionally says the FDA guidelines that defend secondary patents on medication — that enable patent thicketing — are based mostly on a very unsuitable interpretation of Hatch-Waxman.
And tells us he’s working up a problem, with assist from AI instruments like Claude.
He’s 86 years previous. And he doesn’t appear inclined to cease.
Alfred Engelberg: It so modified my life and I did so nicely by it, I believed, how can I not tackle this downside? Who’s gonna do it if I don’t do it?
Dan: He’s bought the time. Money’s no object. And he is aware of the territory in addition to anyone. He helped create it.
Alfred Engelberg: So it’s, it’s my obligation actually. It’s that form of Jewish guilt. What can I inform you? I’m paying again for the bingo recreation.
Dan: So we’ve gone again greater than fifty years on the query: Why aren’t there extra generic medication? We’ve discovered why we’ve bought those we’ve got, and what stands in the best way of getting extra.
And that’s simply in time. Because this spring the U.S. Supreme Court will hear arguments in a case that might limit the generic drug pipeline even additional. It might have main implications.
And understanding what they’re requires the entire 101 we’ve lined right here. We’ll have that story for you in just a few weeks. Til then, care for your self.
This episode of An Arm and a Leg was produced by Emily Pisacreta, with assist from Dan Weissmann— and edited by Ellen Weiss.
Adam Raymonda is our audio wizard.
Our music is by Dave Weiner and Blue Dot Sessions.
Claire Davenport is our engagement producer.
Sarah Ballema is our Operations Manager. Bea Bosco is our consulting director of operations.
This sequence — An Arm and a Leg 101 — is made potential partially by help from Arnold Ventures.
An Arm and a Leg is produced in partnership with KFF Health News. That’s a nationwide newsroom producing in-depth journalism about well being points in America and a core program at KFF, an impartial supply of well being coverage analysis, polling, and journalism.
Zach Dyer is senior audio producer at KFF Health News. He’s editorial liaison to this present.
An Arm and a Leg is distributed by KUOW, Seattle’s NPR information station.
And due to the Institute for Nonprofit News for serving as our fiscal sponsor.
They enable us to simply accept tax-exempt donations. You can be taught extra about INN at INN.org.
Finally, thanks to all people who helps this present financially.
You can take part any time at arm and a leg present, dot com, slash: help.
“An Arm and a Leg” is a co-production of KFF Health News and Public Road Productions.
For extra from the crew at “An Arm and a Leg,” subscribe to its weekly publication, First Aid Kit. You may observe the present on Facebook, Instagram, LinkedIn, and Bluesky. And when you’ve bought tales to inform concerning the well being care system, the producers would like to hear from you.
To hear all KFF Health News podcasts, click here.
And subscribe to “An Arm and a Leg” on Spotify, Apple Podcasts, Pocket Casts, or wherever you take heed to podcasts.
src=”//platform.twitter.com/widgets.js” charset=”utf-8″>